<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017589</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068721</org_study_id>
    <secondary_id>GENTA-GA210</secondary_id>
    <secondary_id>UCCRC-10928</secondary_id>
    <nct_id>NCT00017589</nct_id>
  </id_info>
  <brief_title>Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and&#xD;
      either kill them or deliver tumor-killing substances to them without harming normal cells.&#xD;
      Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more&#xD;
      sensitive to the drug.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab&#xD;
      ozogamicin in treating older patients who have relapsed acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete response rate of elderly patients with relapsed CD33-positive&#xD;
           acute myeloid leukemia treated with oblimersen and gemtuzumab ozogamicin.&#xD;
&#xD;
        -  Determine the overall response rate and duration of response of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oblimersen IV continuously on days 1-7 and 15-22 and gemtuzumab ozogamicin&#xD;
      IV over 2 hours on days 4 and 18.&#xD;
&#xD;
      Patients are followed monthly for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-100 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CD33+ acute myeloid leukemia (AML)&#xD;
&#xD;
               -  In first relapse from chemotherapy&#xD;
&#xD;
               -  Complete response lasting at least 3 months before relapse&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
          -  No secondary leukemia or history of antecedent hematologic disorder prior to initial&#xD;
             onset of AML (e.g., myelodysplasia)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  60 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC less than 30,000/mm^3&#xD;
&#xD;
          -  No bleeding or coagulation disorder except disease-related disseminated intravascular&#xD;
             coagulation&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  PT and PTT no greater than 1.5 times upper limit of normal OR&#xD;
&#xD;
          -  INR no greater than 1.3&#xD;
&#xD;
          -  No history of chronic hepatitis or cirrhosis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other concurrent medical disease that would preclude study entry&#xD;
&#xD;
          -  No known hypersensitivity to phosphorothioate-containing oligonucleotides, gemtuzumab&#xD;
             ozogamicin or any of its components, E. coli protein, or any product produced in E.&#xD;
             coli&#xD;
&#xD;
          -  No other concurrent malignancy&#xD;
&#xD;
          -  No known human anti-human antibodies&#xD;
&#xD;
          -  No uncontrolled seizure disorder&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior allogeneic or autologous stem cell transplantation&#xD;
&#xD;
          -  No prior therapy with an anti-CD33 antibody (e.g., gemtuzumab ozogamicin or M195)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior cancer chemotherapy except intrathecal chemotherapy or&#xD;
             hydroxyurea&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior systemic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior antileukemic therapy and recovered&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley R. Frankel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Genta Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genta Incorporated</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul;30(7):777-83. Epub 2006 May 26.</citation>
    <PMID>16730060</PMID>
  </results_reference>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

